IOL Chemicals and Pharma gets EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress gastric acid secretion.;

Published On 2022-11-07 06:00 GMT | Update On 2022-11-07 13:00 GMT

Ludhiana: IOL Chemicals and Pharmaceuticals Limited (IOL), a manufacturer of pharmaceutical (APIs) and specialty chemicals, has announced receiving EDQM certification to supply Pantoprazole Sodium Sesquihydrate API across European market.

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress gastric acid secretion.

The company started production of Pantoprazole Sodium Sesquihydrate in Q3 FY 2020 at its Punjab based facility.

With this CEP certification, the Company will now be able to export it to entire Europe. IOL currently, has a total capacity of producing 240 TPA of Pantoprazole Sodium Sesquihydrate.

Established in 1986, IOL Chemicals and Pharmaceuticals

has a wide presence across major therapeutic categories like, Pain Management, anticonvulsants, antidiabetes, anti- cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with 17 MW captive Co-Generation plant for self -reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified. IOL's overseas customers are spread out across several countries including UK, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Read also: IOL Chemicals gets Korean approval for Ibuprofen, Fenofibrate

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

IOL Chemicals and Pharma gets EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress gastric acid secretion.;

Similar News

AstraZeneca Imfinzi approved in EU for muscle-invasive bladder cancer

Pfizer's Abrocitinib Phase III Data Accepted by CDSCO Expert Committee

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report